Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Nimotuzumab-gemcitabine combo improves survival in metastatic pancreatic cancer patients

07 Aug 2017

The combination of nimotuzumab and gemcitabine is safe and well tolerated in the treatment of patients with locally advanced or metastatic pancreatic cancer, significantly improving 1-year overall survival (OS) and progression-free survival (PFS) rates especially in those with KRAS wild-type tumours, according to a study.

A total of 192 patients with previously untreated, unresectable, locally-advanced or metastatic pancreatic cancer were randomly assigned to receive gemcitabine (1,000 mg/m2, administered as a 30-minute infusion once weekly for 3 weeks, followed by a 1-week rest) plus either nimotuzumab (fixed dose of 400 mg as a 30-minute infusion) or placebo. Treatment was given until progression or unacceptable toxicity.

Of the patients, 186 (average age 63.6 years) were evaluated for efficacy and safety. The primary endpoint of OS was markedly higher in the nimotuzumab vs the placebo group (median, 8.6 vs 6.0 months; hazard ratio [HR], 0.69; p=0.0341). PFS was similarly better in the group receiving nimotuzumab (median, 5.1 vs 3.4 months; HR, 0.68; p=0.0163).

The corresponding 1-year OS and PFS were 34 and 22 percent for the gemcitabine plus nimotuzumab group vs 19 and 10 percent for the gemcitabine plus placebo group (HR for OS, 0.69; p=0.03; HR for PFS, 0.68; p=0.02).

Of note was the significantly better OS observed among patients with KRAS wild-type tumours than those with KRAS mutations (11.6 vs 5.6 months; p=0.03).

In terms of safety, very few grade 3/4 toxicities were reported. Commonly reported adverse events in the gemcitabine plus nimotuzumab group included chills, fatigue and pyrexia.

Nearly always fatal, pancreatic cancer has a 5-year survival rate of below 5 percent. Palliative chemotherapy remains the treatment of choice, given that most patients present with advanced disease. [Ann Oncol 2013;24:792-800; Ther Adv Med Oncol 2015;7:68-84; Oncology (Williston Park) 2014;28:70-74]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.